Conclusion
In summary, we present the experience of a moderate volume of VOM
ethanol infusions in routine practice of AF ablation from a single
medical center. Our demonstration of the feasibility of growing this
program in a previously inexperienced center should allay trepidation to
other operators or readers considering adopting this technique into
their repertoire. While the high efficacy is laudable, the rate of
delayed pericardial effusions should be noted and operators prepared for
this complication with early echocardiographic follow-up and for
informed consent discussions with patients. Further study of VOM ethanol
infusion is needed to determine the marginal benefit and risks across
centers.